Drug intelligence / Profile preview

Uniflu

Development stage: Unknown
Lead developer: VA Pharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Uniflu is a recombinant universal influenza vaccine developed by VA Pharma Limited Liability Company. It is designed to induce immunity against a broad range of influenza viruses. The vaccine is currently being investigated in healthy volunteers to assess its reactogenicity, safety, and immunogenicity.

Targets

M2e (Influenza A matrix protein 2 ectodomain)

Beyond the preview

Go deeper on Uniflu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uniflu.

Explore the full profile